ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) released its quarterly earnings results on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), Zacks reports.
ESSA Pharma Stock Performance
Shares of EPIX opened at $1.66 on Tuesday. ESSA Pharma has a 12-month low of $1.40 and a 12-month high of $10.94. The business’s fifty day moving average price is $1.72 and its 200 day moving average price is $3.70.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on EPIX shares. Piper Sandler cut ESSA Pharma from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $2.00 in a research note on Monday, November 4th. Oppenheimer cut ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th. Finally, Jefferies Financial Group cut ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
- Five stocks we like better than ESSA Pharma
- What Are Dividend Champions? How to Invest in the Champions
- 3 Undervalued Stocks You Don’t Want to Overlook
- What is the S&P/TSX Index?
- Fintech vs. Traditional Finance: Showdown of Nu, SoFi, and Chubb
- Stock Splits, Do They Really Impact Investors?
- Onsemi Stock: Signs Point to a Powerful Rebound
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
